Neurocrine(NBIX) Prnewswire·2025-02-27 21:05Core Insights - Neurocrine Biosciences announced positive top-line data from the Phase 4 KINECT-PRO study, demonstrating the effectiveness of INGREZZA (valbenazine) in improving the physical, social, and emotional impacts of tardive dyskinesia (TD) in patients, regardless of the severity of TD or underlying psychiatric conditions [1][2][4] Group 1: Study Overview - The KINECT-PRO study is the first to utilize multiple clinically validated scales to assess the patient-reported impact of INGREZZA on TD [1][3] - The study enrolled 59 patients who received once-daily doses of INGREZZA (40 mg, 60 mg, or 80 mg) for up to 24 weeks, with 52 patients completing the study [2][5] - The primary objective was to evaluate changes in patient-reported physical and socio-emotional impacts of TD, while the secondary objective focused on clinician- and patient-reported changes in TD severity [3][4] Group 2: Results and Findings - Significant and sustained improvements were observed in all three patient-reported outcome measures, with improvements noted as early as four weeks at the lowest dose of 40 mg [4] - AIMS scores indicated sustained reductions in involuntary movements across different TD severity levels and underlying psychiatric conditions [4] - The safety and tolerability profile of INGREZZA remained consistent with previous studies, with no new safety concerns identified [4] Group 3: About INGREZZA - INGREZZA is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for treating adults with tardive dyskinesia and chorea associated with Huntington's disease [8][9] - The drug is designed to be taken once daily without the need for titration, offering a therapeutic dose from day one [8][10] - INGREZZA is available in 40 mg, 60 mg, and 80 mg capsules, and a sprinkle formulation is also available for patients who have difficulty swallowing [10][19]